Nisoldipine Articles

Skyepharma further reduces loss in first half

8 September 2008

Sciele Pharma reaffirms 2007 guidance

21 January 2008

Stock Commentary - Europe - week to Jan 7, 2008

14 January 2008

FDA clears new Sular formulations

7 January 2008

FDA accepts Sular sNDA

17 September 2007

Stock Commentary - Europe - week to May 14, 2007

21 May 2007

New Sular formulation bioequivalent in trials

21 May 2007

First Horizon sees growing partnership with Bayer

16 January 2006

AstraZeneca and Bayer stop co-marketing Baymycard in Japan

1 April 2002

First Horizon buys US Sular rights from AstraZeneca

25 February 2002

-Forest Laboratories acquires exclusive UK and Ireland marketing rights to

23 February 1999

Calcium Channel Blocker Link To Suicide

11 March 1998

Zeneca Sees Strong Growth Against The Odds

8 August 1997

Zeneca Breaks Records In 1996 As New Products Are Launched

17 March 1997

Benefits Of Bayer's Nisoldipine Shown By DEFIANT II Study

20 January 1997

Bayer's Syscor Launched In UK

25 November 1996

Strong Fundamentals On Show At Zeneca

19 August 1996

Zeneca / Bayer: Sular agreement

22 January 1996

US FDA Approving Fewer NMEs, But Faster, In 1995

11 September 1995

JAMA Study Ups Debate Over Calcium Blockers

4 September 1995

Calcium Blockers In HF: V-HeFT III & DEFIANT II

4 September 1995

Bayer/Zeneca Deal On US Marketing Of Sular

14 August 1995

Bayer hold back Nisocor

22 May 1995

Miles Considers Licensing

13 February 1995

Showing 1-24 of 24 articles

Go to beginningPrevious
  • 1
NextGo to end